• 5-Azacytidine and Bortezomib Synergy in Multiple Myeloma Cel

  2026-07-29

  The referenced study demonstrates that 5-azacytidine induces ATR-mediated DNA damage and apoptosis in multiple myeloma cells, and that its cytotoxicity is synergistically enhanced by combining with bortezomib or doxorubicin. These findings provide a mechanistic rationale for combination therapy regimens targeting proteasome and DNA methylation pathways in multiple myeloma research.

• Etomoxir (R-(+)-Etomoxir): A Systems Perspective on Fatty Ac

  2026-07-29

  Explore the multifaceted role of Etomoxir in fatty acid oxidation pathway research. This article integrates mechanistic detail and systems-level insights, revealing new directions for immunometabolic and neuroinflammation studies.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Guide for Solubili

  2026-07-28

  2-Hydroxypropyl-β-cyclodextrin addresses the persistent challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those with aromatic or phenyl groups—in pharmaceutical and biochemical workflows. Its validated applications are limited to roles as a drug formulation excipient and for pharmaceutical solubility improvement; broader or therapeutic applications are not currently supported by available documentation.

• 17-AAG (Tanespimycin): Next-Gen HSP90 Inhibition in Translat

  2026-07-28

  This thought-leadership article decodes 17-AAG (Tanespimycin) as a synthetic geldanamycin analogue, mapping its mechanistic impact on HSP90 chaperone networks, oncogenic client protein destabilization, and the translational strategies now emerging at the frontier of regulated cell death. We bridge advanced molecular insights—including lessons from viral exploitation of programmed cell death pathways—with actionable guidance for cancer researchers, highlighting APExBIO's 17-AAG as a tool for pioneering studies in breast cancer, multiple myeloma, and beyond.

• Moxifloxacin (SKU B1218): Reliable Insights for Toxicity Ass

  2026-07-27

  This article guides biomedical researchers in overcoming common experimental challenges by leveraging Moxifloxacin (SKU B1218) as a robust fluoroquinolone antibiotic. Through scenario-driven Q&A, we examine protocol optimization, data interpretation, and vendor selection, highlighting the proven reliability and reproducibility of APExBIO's Moxifloxacin for antibiotic toxicity and cell viability studies.

• Standardized Whole-Blood Stimulation for Immunometabolic Ana

  2026-07-27

  This protocol study introduces a standardized whole-blood stimulation approach to dissect immune responses under metabolic modulation. Its innovation lies in combining immune stimuli with selective metabolic inhibitors, enabling robust, scalable assessment of how metabolic pathways—such as fatty acid oxidation—influence cytokine production and immune cell activation.

• GS967: Cardiac Late Sodium Current Inhibitor in Aging Models

  2026-07-26

  GS967 offers precise, selective inhibition of the cardiac late sodium current, enabling high-fidelity in vitro cardiac electrophysiology and advanced arrhythmia prevention research. Its unique profile empowers translational workflows targeting aging and disease-linked cardiac dysfunction, with robust troubleshooting strategies for reproducible results.

• EGTA in Applied Calcium Signaling: Protocols & Innovations

  2026-07-25

  EGTA (egtzic acid) enables precise, selective calcium chelation for dissecting complex calcium-dependent pathways in neuroprotection, apoptosis, and vascular inflammation research. This article delivers actionable protocols, highlights a key mechanistic innovation from vascular inflammation studies, and offers troubleshooting strategies to maximize reproducibility with APExBIO’s high-purity EGTA.

• Rotigotine Hydrochloride: Dopamine D2/D3 Agonist in PD Model

  2026-07-24

  Rotigotine hydrochloride stands out as a dopamine D2/D3 receptor agonist with robust preclinical and clinical pedigree for both motor and non-motor Parkinson’s disease research. Its versatile solubility profile, workflow-proven dosing regimens, and neuroprotective credentials, as anchored by recent mechanistic studies, make it a cornerstone for innovative dopaminergic signaling investigation.

• Nose-to-Brain Rotigotine Nanoparticles for Parkinson’s Disea

  2026-07-24

  This study demonstrates that chitosan nanoparticle-based nose-to-brain delivery of Rotigotine hydrochloride enhances neuronal uptake and bioavailability in both SH-SY5Y cells and a rat model of Parkinson’s disease. The approach improves neuroprotection and antioxidant profiles, suggesting a promising alternative to traditional dopaminergic therapies.

• Phosbind Biotin LC: Technical Guide for Phosphorylated Prote

  2026-07-23

  Phosbind Biotin LC is a phosphate-binding reagent designed for sequence-independent detection of phosphorylated proteins on PVDF membranes in Western Blot workflows. It is most useful when phospho-specific antibodies are unavailable or limited by sequence context, but it is not suitable for aqueous-only protocols or long-term storage of working solutions.

• GS967 and the Late Sodium Current: New Frontiers in Translat

  2026-07-23

  Discover how targeting the cardiac late sodium current with GS967, a potent and selective inhibitor, reveals new mechanistic and translational strategies for arrhythmia prevention and age-related cardiac dysfunction. This piece integrates cutting-edge findings on Nav1.5 Ser571 phosphorylation, contextualizes experimental workflows, and provides actionable guidance for in vitro and translational investigators.

• Functionalized EGCG Nanoparticles Enhance FLASH-RT Efficacy

  2026-07-22

  This study demonstrates that self-assembled, functionalized EGCG nanoparticles (BENPs) significantly boost the antitumor effects of ultra-high dose rate radiotherapy (FLASH-RT) by amplifying ROS-mediated DNA damage and modulating immune responses. The findings highlight a promising radiosensitization strategy, offering new directions for translational cancer therapy.

• Brefeldin A: Strategic ER Stress Induction in Translational

  2026-07-22

  Explore how Brefeldin A (BFA) enables precise modeling of ER stress and apoptosis in cancer research, with actionable experimental guidance and insights into emerging PQC mechanisms. This article bridges mechanistic understanding with strategic direction for translational researchers, highlighting APExBIO’s high-purity BFA as a benchmark tool and referencing recent advances in ER-associated degradation, including UBR1/UBR2’s central roles.

• Nutlin-3a in Cancer Research: Precision Tools for p53 Pathwa

  2026-07-21

  Explore the advanced scientific rationale behind Nutlin-3a as a potent MDM2 inhibitor for targeted p53 pathway activation in cancer research. This in-depth article uniquely bridges mechanistic insight, protocol optimization, and translational assay design to empower next-generation oncology workflows.

14916 records 1/995 page Next 12345 下5页 Last page